文献速递炎症性肠病

REMIT-UC:托法替布治疗中重度活动性溃疡性结肠炎的真实世界有效性与安全性:加拿大IBD研究联盟多中心全国队列研究

REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort Study.
PubMed 文献 · Am J Gastroenterol · 2022-12-14

REMIT-UC为加拿大多中心队列研究,纳入334例连续成人溃疡性结肠炎门诊患者,评估托法替布真实世界有效性与安全性。第12、24、52周临床缓解率分别为35.3%、36.0%、35.2%,内镜缓解率分别为18.5%、23.0%、25.7%。减量后44.5%患者失应答,再升级至10 mg每日两次可部分挽回应答。

要点

  • 托法替布治疗溃疡性结肠炎第52周临床缓解率为35.2%(93/264)。
  • 基线Mayo内镜评分3分和既往生物制剂失败是减量后失应答的预测因素。
  • 减量后44.5%患者失应答,再升级至10 mg每日两次仅54.9%挽回应答。

核心结论

  • 约三分之一溃疡性结肠炎患者接受托法替布治疗达到临床缓解,严重不良事件较少。
  • 减量后约半数患者失应答,增加维持剂量仅部分挽回应答。
  • 具有不良预后因素者应被告知继续高剂量托法替布的风险与获益。

研究设计与样本

  • REMIT-UC为加拿大多中心队列研究,对334例连续成人溃疡性结肠炎门诊患者进行标准化数据收集。
  • 主要结局为临床缓解和内镜缓解达标,安全性结局以发病率(每100患者年暴露的事件数)报告。
  • 采用多变量Cox比例风险模型评估托法替布减量至5 mg每日两次后失应答的预测因素。

主要发现

  • 第12、24、52周临床缓解率分别为35.3%(106/300)、36.0%(104/289)、35.2%(93/264)。
  • 第12、24、52周内镜缓解率分别为18.5%(15/81)、23.0%(28/122)、25.7%(35/136)。
  • 严重感染、带状疱疹和静脉血栓栓塞的发病率分别为2.1[0.9-4.2]、0.5[0.1-1.9]和1.1[0.3-2.7](事件/100患者年)。
  • 应答者中44.5%(109/245)在随访期间失应答,再升级至10 mg每日两次的患者中54.9%(39/71)挽回应答。
  • 基线Mayo内镜评分3分(校正风险比3.60[95%置信区间:1.70-7.62])和既往生物制剂失败(校正风险比3.89[95%置信区间:1.28-11.86])与减量后失应答风险升高相关。

临床怎么用

  • 作者认为,具有不良预后因素的患者应被告知继续高剂量托法替布的风险与获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We aimed to evaluate the real-world effectiveness and safety of tofacitinib for the treatment of ulcerative colitis (UC). METHODS: REMIT-UC is a Canadian multicenter cohort study. Standardized data collection was performed on 334 consecutive adult outpatients with UC treated with tofacitinib. The primary outcomes were achievement of clinical and endoscopic remission. Safety outcomes were reported using incidence rates (events/100 patient-years of exposure). A multivariable Cox proportional hazards model was used to evaluate predictors of loss of response after tofacitinib dose de-escalation to 5 mg twice daily (BID). RESULTS: Clinical remission was achieved by 35.3% (106/300), 36.0% (104/289), and 35.2% (93/264) of patients at weeks 12, 24, and 52, respectively. Endoscopic remission was achieved by 18.5% (15/81), 23.0% (28/122), and 25.7% (35/136) of patients at weeks 12, 24, and 52, respectively. Incidence of serious infections, herpes zoster, and venous thromboembolism were 2.1 [0.9-4.2], 0.5 [0.1-1.9], and 1.1 [0.3-2.7], respectively. Among responders, 44.5% (109/245) lost response during follow-up, which was recaptured in 54.9% (39/71) of patients who re-escalated to 10 mg BID. Patients with a baseline Mayo endoscopic score of 3 (adjusted hazard ratio 3.60 [95% confidence interval: 1.70-7.62]) and prior biologic failure (adjusted hazard ratio 3.89 [95% confidence interval: 1.28-11.86]) were at a higher risk for losing response after dose reduction. DISCUSSION: One-third of patients with UC treated with tofacitinib achieved clinical remission with few serious adverse events. However, half of patients lost response with de-escalation, which was only partially recaptured with increasing the maintenance dose. Those with negative prognostic factors should be counselled about the risks and benefits of continuing high doses of tofacitinib.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Ma C, Panaccione R, Xiao Y, et al. REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort Study. Am J Gastroenterol. 2022. PMID: 36580497. doi:10.14309/ajg.0000000000002129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。